Literature DB >> 533264

Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

T P Felegie, V L Yu, L W Rumans, R B Yee.   

Abstract

Pseudomonas maltophilia is resistant to most of the commonly used antimicrobial agents including those active against Pseudomonas aeruginosa. The susceptibility of 14 clinical isolates of P. Maltophilia to 18 antimicrobial agents was determined by broth dilution testing. All organisms were susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), minocycline, and LY127935. A total of 87 and 79% of the organisms were susceptible in vitro to colistin and chloramphenicol, respectively. With the exception of sisomicin, the organisms were resistant to the aminoglycosides. Of 21 combinations of antimicrobials examined for synergy, only the combination of TMP-SMZ with carbenicillin was consistently (86%) synergistic in vitro. Supplementation of the testing media with calcium and magnesium increased the minimal inhibitory concentrations for the aminoglycosides, the penicillins, and TMP-SMZ against P. maltophilia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533264      PMCID: PMC352962          DOI: 10.1128/AAC.16.6.833

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections.

Authors:  R C Ostenson; B T Fields; C M Nolan
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

3.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Distribution in clinical material and identification of Pseudomonas maltophilia.

Authors:  B Holmes; S P Lapage; B G Easterling
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

6.  Susceptibilities of Pseudomonas species to tetracycline, minocycline, gentamicin, and tobramycin.

Authors:  R C Tilton; O Steingrimsson; R W Ryan
Journal:  Am J Clin Pathol       Date:  1978-04       Impact factor: 2.493

7.  Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  J A Washington; R J Snyder; P C Kohner; C G Wiltse; D M Ilstrup; J T McCall
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

8.  Pseudomonas maltophilia causing heroin-associated infective endocarditis.

Authors:  V L Yu; L W Rumans; E J Wing; R McLeod; F N Sattler; R M Harvey; S C Deresinski
Journal:  Arch Intern Med       Date:  1978-11

9.  Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.

Authors:  C E Nord; T Wadström; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

10.  Pseudomonas maltophilia pseudosepticemia.

Authors:  J D Semel; G M Trenholme; A A Harris; J E Jupa; S Levin
Journal:  Am J Med       Date:  1978-03       Impact factor: 4.965

View more
  27 in total

1.  Pseudomonas and all that.

Authors:  C A Hart; C Winstanley
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

Review 2.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

3.  Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

Authors:  B Schable; D L Rhoden; W R Jarvis; J M Miller
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

4.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873.

Authors:  Y Saino; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia.

Authors:  P F Wheat; T G Winstanley; R C Spencer
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

Review 9.  Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  R G Munter; A M Yinnon; Y Schlesinger; C Hershko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

10.  Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients.

Authors:  S Horster; L Bader; U Seybold; I Eschler; K G Riedel; J R Bogner
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.